Provided by Tiger Trade Technology Pte. Ltd.

Merck

118.10
-1.5300-1.28%
Post-market: 117.90-0.2000-0.17%19:57 EDT
Volume:11.08M
Turnover:1.31B
Market Cap:293.13B
PE:16.22
High:121.64
Open:120.57
Low:117.22
Close:119.63
52wk High:125.14
52wk Low:73.31
Shares:2.48B
Float Shares:2.48B
Volume Ratio:1.33
T/O Rate:0.45%
Dividend:3.24
Dividend Rate:2.74%
EPS(TTM):7.28
EPS(LYR):7.28
ROE:36.88%
ROA:12.04%
PB:5.57
PE(LYR):16.22

Loading ...

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

GlobeNewswire
·
Mar 25

Merck & Co Inc - Deal Value About $5.7 Bln Net of Cash, 31% Premium to 60-Day Vwap as of March 24, 2026

THOMSON REUTERS
·
Mar 25

Merck & Co Inc - Deal Expected to Close in Q2 2026 With $5.8 Bln or About $2.35 per Share Charge in Q2 and FY2026 Results

THOMSON REUTERS
·
Mar 25

Merck & Co Inc - Deal Approved by Both Boards; Closing Subject to Majority of Terns Stockholders Tendering Shares

THOMSON REUTERS
·
Mar 25

Deals of the day-Mergers and acquisitions

Reuters
·
Mar 25

Terns Pharmaceuticals Shares up 14.1% Premarket After FT Reports Merck Nears $6 Bln Acquisition of Co

THOMSON REUTERS
·
Mar 25

Merck Nears Acquisition of Terns Pharmaceuticals to Strengthen Blood Cancer Treatment Portfolio

Stock News
·
Mar 25

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

Reuters
·
Mar 25

BRIEF-Merck Nears $6Bn Biotech Deal To Boost Cancer Drug Pipeline - Ft

Reuters
·
Mar 25

Talks Between Merck and Terns Were at an Advanced Stage and Deal Could Be Reached in Coming Days - FT

THOMSON REUTERS
·
Mar 25

Merck's All-Cash Deal Is Expected to Value Terns at Roughly $6Bn - FT

THOMSON REUTERS
·
Mar 25

Merck Nears $6Bn Biotech Deal to Boost Cancer Drug Pipeline - FT

THOMSON REUTERS
·
Mar 25

Quotient Therapeutics Announces Collaboration With Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology

THOMSON REUTERS
·
Mar 24

Is Long-Term GARDASIL Protection Data Reframing The Vaccine Investment Case For Merck (MRK)?

Simply Wall St.
·
Mar 24

Merck & Co. Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 24

Merck’s Emerging HIV Franchise: Undervalued Long-Acting Opportunity in a $25B+ Market Supporting a Buy Rating

TIPRANKS
·
Mar 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Chemed (CHE) and PROCEPT BioRobotics (PRCT)

TIPRANKS
·
Mar 22

Merck Is Maintained at Neutral by Citigroup

Dow Jones
·
Mar 21

Merck price target raised to $125 from $120 at Citi

TIPRANKS
·
Mar 20

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Merck & Company (MRK)

TIPRANKS
·
Mar 20